Omalizumab in patients with chronic spontaneous urticaria: A systematic review and GRADE assessment

British Journal of Dermatology

Volumn 173, Issue 2, 2015, Pages 404-415

  Urgert, M C ^a   Van Den Elzen, M T ^b   Knulst, A C ^b   Fedorowicz, Z ^c   Van Zuuren, E J ^d  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Cochrane Collaboration Bahrain Branch ^*  (Bahrain)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

OMALIZUMAB; PLACEBO; ANTIALLERGIC AGENT;

ARTHRALGIA; CHRONIC SPONTANEOUS URTICARIA; CHRONIC URTICARIA; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE ACTIVITY; DRUG INDUCED HEADACHE; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; META ANALYSIS; OUTCOME ASSESSMENT; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SINUSITIS; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; CHRONIC DISEASE; TREATMENT OUTCOME; URTICARIA;

ANTI-ALLERGIC AGENTS; CHRONIC DISEASE; HUMANS; OMALIZUMAB; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; URTICARIA;

EID: 84941193027     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13845     Document Type: Review

References (27)

1. Zuberbier T, Aberer W, Asero R, et al,. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014; 69: 868-87.
2. Baiardini I, Giardini A, Pasquali M, et al,. Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy. Allergy 2003; 58: 621-3.
3. 2LEN task force report. Allergy 2011; 66: 317-30.
4. Vonakis BM, Saini SS,. New concepts in chronic urticaria. Curr Opin Allergy Clin Immunol 2008; 20: 709-16.
5. European Medicines Agency. Summary of product characteristics Xolair [WWW document]. 2014. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000606/WC500057298.pdf (last accessed 6 July 2015).
6. Beck LA, Marcotte GV, MacGlashan D, et al,. Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol 2004; 114: 527-30.
7. Saini S, MacGlashan D,. How IgE upregulates the allergic response. Curr Opin Allergy Clin Immunol 2002; 14: 694-7.
8. Schünemann H, Brozek J, Guyatt G, Oxman A, eds. GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. Updated October 2013. The GRADE Working Group, 2013 [WWW doument]. Available at: www.guidelinedevelopment.org/handbook (last accessed 6 July 2015).
9. Bernstein JA, Lang DM, Khan DA, et al,. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol 2014; 133: 1270-7.
10. Higgins JPT, Green S,. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011 [WWW document]. Available at: www.cochrane-handbook.org [last accessed 6 July 2015].
11. Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
12. Hochhaus G, Brookman L, Fox H, et al,. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003; 19: 491-8.
13. Maurer M, Altrichter S, Bieber T, et al,. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011; 128: 202-9.e5.
14. Kaplan A, Ledford D, Ashby M, et al,. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013; 132: 101-9.
15. Maurer M, Rosén K, Hsieh H-J, et al,. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013; 368: 924-35.
16. Saini S, Rosen KE, Hsieh H-J, et al,. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011; 128: 567-73.e1.
17. Saini SS, Bindslev-Jensen C, Maurer M, et al,. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol 2015; 135: 67-75.
18. Gober L, Sterba P, Eckman J, Saini S,. Effect of anti-IgE (omalizumab) in chronic idiopathic urticaria (CIU) patients. J Allergy Clin Immunol 2008; 121: 567.
19. Młynek A, Zalewska-Janowska A, Martus P, et al,. How to assess disease activity in patients with chronic urticaria? Allergy 2008; 63: 777-80.
20. Baiardini I, Pasquali M, Braido F, et al,. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). Allergy 2005; 60: 1073-8.
21. Mathias SD, Crosby RD, Zazzali JL, et al,. Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2012; 108: 20-4.
22. European Medicines Agency. Assessment report Xolair [WWW document]. 2013. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Assessment-Report-Variation/human/000606/WC500164453.pdf (last accessed 6 July 2015).
23. Mitchell S, Balp M-M, Samuel M, et al,. Systematic review of treatments for chronic spontaneous urticaria with inadequate response to licensed first-line treatments. Int J Dermatol 2014. DOI: 10.1111/ijd.12727
24. National Institute for Health and Care Excellence. Single technology assessment template [WWW document]. Available at: http://www.nice.org.uk/article/pmg9/chapter/6-the-appraisal-of-the-evidence-and-structured-decision-making (last accessed 6 July 2015).
25. Carrillo DC, Borges MS, García E, et al,. Omalizumab vs. placebo in the management of chronic idiopathic urticaria: a systematic review. World Allergy Organ J 2014; 7: 72.
26. Durack A, Matin RN,. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria: a critical appraisal. Br J Dermatol 2014; 171: 10-13.
27. Rosén K, Maurer M, Hsieh H, et al,. Response to: 'Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria: a critical appraisal'. Br J Dermatol 2014; 171: 15-16.